Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferon therapy for multiple sclerosis.

K P Johnson1, H S Panitch

  • 1Department of Neurology, University of Maryland School of Medicine, Baltimore.

Maryland Medical Journal (Baltimore, Md. : 1985)
|July 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dendritic and parallel processing of visual threats in the retina control defensive responses.

Science advances·2020
Same author

Development and Characterization of 12 Novel Polymorphic Microsatellite Loci for the Mammal Chewing Louse Geomydoecus aurei (Insecta: Phthiraptera) and a Comparison of Next-Generation Sequencing Approaches for Use in Parasitology.

The Journal of parasitology·2017
Same author

Patterns of cryptic host specificity in duck lice based on molecular data.

Medical and veterinary entomology·2016
Same author

Parallel evolution in the major haemoglobin genes of eight species of Andean waterfowl.

Molecular ecology·2009
Same author

Clinical response to glatiramer acetate correlates with modulation of IFN-gamma and IL-4 expression in multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2007
Same author

A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients.

Multiple sclerosis (Houndmills, Basingstoke, England)·2006
Same journal

Adherence to the JNC VI guidelines for the treatment of hypertension in the resident clinic.

Maryland medical journal (Baltimore, Md. : 1985)·2000
Same journal

Seroprevalence study of Hantavirus infection in the community based population.

Maryland medical journal (Baltimore, Md. : 1985)·2000
Same journal

Pneumomediastinum: the Valsalva crunch.

Maryland medical journal (Baltimore, Md. : 1985)·2000
Same journal

Hepatic hydrothorax: diagnosis and management. Case report and review of the literature.

Maryland medical journal (Baltimore, Md. : 1985)·2000
Same journal

A case of post-streptococcal reactive arthritis.

Maryland medical journal (Baltimore, Md. : 1985)·2000
Same journal

Sexual practices of older adults in a high HIV prevalence environment.

Maryland medical journal (Baltimore, Md. : 1985)·2000
See all related articles

Beta interferon therapy may improve suppressor cell function and inhibit gamma interferon activity. This suggests beta interferon could significantly reduce relapse rates in multiple sclerosis patients.

Area of Science:

  • Immunology
  • Neuroscience

Background:

  • Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system.
  • The role of interferon-gamma (IFN-γ) and suppressor cells in MS pathogenesis is under investigation.

Purpose of the Study:

  • To evaluate the therapeutic potential of beta interferon (IFN-β) in managing multiple sclerosis.
  • To investigate the effects of IFN-β on suppressor cell function and IFN-γ activity in the context of MS.

Main Methods:

  • Laboratory analysis of immune cell function.
  • Assessment of interferon activity in vitro or in preclinical models.

Main Results:

  • Beta interferon therapy demonstrated an improvement in suppressor cell function.

Related Experiment Videos

  • Gamma interferon activity was observed to be inhibited by beta interferon.

    • Conclusions:

    • The observed immunomodulatory effects support the hypothesis that beta interferon is a viable therapeutic option for multiple sclerosis.
    • Beta interferon may significantly impact relapse rates in patients with multiple sclerosis due to its effects on immune regulation.